Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Aura Biosciences Inc shares valued at $4,925 were purchased by Elazzouzi Amy on Apr 16 ’25. At $5.49 per share, Elazzouzi Amy acquired 897 shares.
Also, Kilroy Conor purchased 7,162 shares, netting a total of over 39,319 in proceeds.
Before that, Elazzouzi Amy had sold 897 shares from its account. In a trade valued at $4,925, the Senior Vice President, Finance traded Aura Biosciences Inc shares for $5.49 each. Upon closing the transaction, the insider’s holdings decreased to 897 shares, worth approximately $0.44 million.
As published in their initiating research note from H.C. Wainwright on July 25, 2024, Aura Biosciences Inc [AURA] has been a Buy and the price target has been revised to $21. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in late July. Earlier on July 19, 2022, JMP Securities initiated its rating. Their recommendation was “a Mkt outperform” for AURA stock.
Analyzing AURA Stock Performance
During the last five days, there has been a surge of approximately 7.85%. Over the course of the year, Aura Biosciences Inc shares have dropped approximately -34.79%. Shares of the company reached a 52-week high of $8.60 on 01/06/25 and a 52-week low of $4.84 on 04/10/25. A 50-day SMA is recorded $6.86, while a 200-day SMA reached $8.34.
Support And Resistance Levels for Aura Biosciences Inc (AURA)
According to the 24-hour chart, there is a support level at 5.26, which, if violated, would cause prices to drop to 5.15. In the upper region, resistance lies at 5.48. The next price resistance is at 5.59. RSI (Relative Strength Index) is 37.20 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.04, which suggests the price will decrease in the coming days. Percent R is at 67.80%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
